参麦注射液治疗充血性心力衰竭的临床观察  

Clinical Study on Effect of Shenmai Injection in Treating Congestive Heart Failure

作　　者：龙明智[1] 王迪斌[1] 杨季明[1] 周丽英[1] 

机构地区：[1]南京医科大学第二附属医院第二临床医学院,南京210011

出　　处：《中国中西医结合杂志》2003年第11期808-810,共3页Chinese Journal of Integrated Traditional and Western Medicine

基　　金：江苏省卫生厅重点资助科研项目(No.Q9703)

摘　　要：目的:观察参麦注射液对充血性心力衰竭心肌损害的疗效。方法:采用随机分组的方法,分别用常规治疗(31例)和常规加参麦注射液治疗(31例),并对慢性心力衰竭进程中各项实验室指标[cAMP、cGMP、血浆肌钙蛋白T(cTnT)、心肌酶谱]变化进行观察。结果:在充血性心力衰竭进程中,早期血浆cAMP/cGMP比值升高,晚期血浆cAMP/cGMP比值降低;cTnT浓度随着心功能恶化呈进行性增高。应用参麦注射液治疗2周后,患者左室收缩功能得到明显改善,未发现严重不良反应。结论:血浆cTnT可作为充血性心力衰竭患者预后判断的一项重要生化指标。参麦注射液是治疗充血性心力衰竭安全有效药物。Objective: To observe the therapeutic effect of Shenmai Injection (SI) in treating congestive heart failure (CHF) . Methods: The changes in cAMP, cGMP, serum cardiac troponin T (cTnT, a specific marker reflecting myocardial injury), creatine kinase (CK) and creatine kinase isoenzyme (CK-MB) were simultaneously monitored in 62 chronic CHF patients, distributed in the two groups, the routine treatment group and the routine treatment + SI group, by randomized grouping method, and the therapeutic effect of the two groups was compared. Results: The plasma cAMP/cGMP ratio increased in early stage and decreased in late stage of the course of CHF. The serum cTnT level was progressively increased along with heart function deterioration. After treated with SI for 2 weeks, the CHF patients' hemodynamics got stable and heart function obviously improved. No serious adverse reaction was found in the therapeutic course. Conclusion: The level of serum cTnT might be taken as a reliable biochemical parameter to predict the prognosis of CHF patients. SI is an effective and safe a-gent in treating CHF.

关 键 词：参麦注射液 充血性心力衰竭 临床观察 中医药疗法 肌钙蛋白T 心功能 

分 类 号：R259[医药卫生—中西医结合]